AgingResearch.NewsJoin free

Phase 4CompletedAge-related condition

A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder

A Phase 4, Open-label, Randomized, Prospective, Interventional Post-authorization Efficacy and Safety Study of Mirabegron 50 mg and 25 mg for the Treatment of Overactive Bladder in Chinese Subjects

Sponsor
Astellas Pharma China, Inc. (Industry)
Enrollment
249 enrolled
Conditions
Urge Incontinence; Overactive Bladder (OAB)
Interventions
mirabegron
Ages
adults, older adults
Registry
NCT04562090

Full record on ClinicalTrials.gov

From the registry

The purpose of this study was to evaluate the efficacy of mirabegron for the treatment of overactive bladder (OAB) in Chinese participants. This study also evaluated the safety of mirabegron for the treatment of OAB in Chinese participants, evaluated other efficacy variables of mirabegron for the treatment of OAB and explored different mirabegron starting doses.

Primary outcomes

  • Change From Baseline (CFB) to the End of 12-Week Treatment Period in Mean Number of Micturition/24 Hours in Mirabegron 50 mg Group

History

  1. Last registry update

  2. Results first posted

  3. Study completion

  4. Primary completion

  5. Started

  6. Registered